跳至主要内容
临床试验/NCT05907772
NCT05907772已完成不适用

Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma: A Multi-center Retrospective Cohort Study in China

Zhejiang University1 个研究点 分布在 1 个国家目标入组 522 人开始时间: 2022年8月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
522
试验地点
1
主要终点
Overall survival

研究概览

简要总结

This is a multi-center study in China to investigate the role of PIVKA-II in HCC recipient selection and prognostic stratification by analyzing the data of 522 recipients with HCC registered in the China Liver Transplant Registry.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The HCC patients received LT with pre-operative PIVKA-II records performed from January 2015 to December 2020, whose clinicopathological data were registered in the CLTR.

排除标准

  • (1) patients who received split LT or simultaneous transplantation, (2) patients who received re-transplantation, (3) patients with macroscopic portal vein tumor thrombosis or other macrovascular invasion, (4) patients with incomplete follow-up or incomplete important parameters records.

结局指标

主要结局

Overall survival

时间窗: January 2015 to December 2020

the overall survival of liver transplant recipient with HCC

次要结局

未报告次要终点

研究者

发起方
Zhejiang University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiao Xu

Professor

Zhejiang University

研究点 (1)

Loading locations...

相似试验